**Gut Microbial Diversity Is Reduced in Smokers with Crohn’s Disease**

Jorrit L. Opstelten, MD, MSc,* Jonathan Plassais, MSc,† Saskia W. C. van Mil, PhD,‡ Emna Achouri, MSc,‡ Matthieu Pichaud, PhD,‡ Peter D. Siersema, MD, PhD,*† Bas Oldenburg, MD, PhD,* and Alessandra C. L. Cervino, PhD‡

**Background:** Smoking has a negative impact on Crohn’s disease (CD), but the mechanisms underlying this association are unclear. We compared the gut microbiota composition of smoking with nonsmoking patients with CD using a metagenomic approach.

**Methods:** Stool samples and clinical data were collected from current smokers and nonsmokers with CD from France and the Netherlands, matched for country, gender, age, disease activity, and body mass index. Fecal DNA was sequenced on an Illumina HiSeq 2500. On average, 40 million paired-end reads were generated per sample. Gene richness and the Shannon index were computed to assess microbial diversity. Wilcoxon’s signed-rank tests for paired samples were performed to detect differences between the 2 groups.

**Results:** In total, 21 smoking and 21 nonsmoking patients with CD were included. Compared with nonsmoking patients, gut microbial gene richness (P = 0.01), genus diversity (P < 0.01), and species diversity (P = 0.01) were decreased in smoking patients. This was accompanied by a reduced relative abundance of the genera *Collinsella* (P = 0.02), *Enterorhabdus* (P = 0.02), and *Gordonibacter* (P = 0.02) in smokers. No statistically significant differences at the species level were observed, although smokers had lower proportions of *Faecalibacterium prausnitzii* (P = 0.10).

**Conclusions:** Gut microbial diversity is reduced in smokers with CD compared with nonsmokers with CD. The microbial profile differs between these groups at the genus level. Future studies should evaluate whether intestinal microbes mediate the adverse effects of smoking in CD.

*(Inflamm Bowel Dis 2016;22:2070–2077)*

**Key Words:** smoking, microbiota, Crohn’s disease, inflammatory bowel disease, sequencing

---

Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD) that is marked by recurrent episodes of intestinal inflammation and may lead to significant complications and disability.1,2 The pathogenesis of this chronic disorder is complex and thought to involve an interaction between host and environmental factors, in which the gut microbiota is considered to play an important role.3 Smoking is one of the strongest environmental risk factors for CD.4 It is consistently associated with an increased risk of developing CD.5 Moreover, smoking has adverse effects on the clinical course with an increased number of relapses and need for medications and surgical interventions among smokers with CD.6–8 Although deleterious effects of smoking on intestinal permeability, the immune system, and epigenetic susceptibility have been reported, the biological mechanisms by which smoking influences the pathogenesis of CD remain unclear.4

With the advent of culture-independent techniques for characterizing microbial communities, the role of the microbiota in health and disease has regained interest. Next-generation sequencing methods have provided powerful tools with regard to in-depth analysis of the microbiome.9–11 Accumulating data highlight the potential impact of environmental factors, such as antibiotic use or diet, on the gut microbiota.12–15 Accordingly, it has been suggested that intestinal microbes could be an important link between smoking and CD.4 Only few studies have specifically investigated the relationship between smoking and gut microbiota in humans.16–18 In a recent interventional study, using different techniques, significant changes were observed in the fecal microbiota of healthy individuals undergoing smoking...
cessation, including an increase in the relative abundance of Firmicutes (*Clostridium cocoides*, *Eubacterium rectale*, and *Clostridium leptum* subgroup) and Actinobacteria (high guanine and cytosine content bacteria and *Bifidobacteria*) and a reduction of Bacteroidetes (*Prevotella spp.* and *Bacteroides* spp.) and Proteobacteria (*b*- and *g*-subgroup). A cross-sectional study using fluorescent in situ hybridization targeting selected bacterial groups reported that smoking patients with active CD exhibited different microbial profiles, with higher *Bacteroides–Prevotella*, compared with nonsmoking patients with CD. Similar results were found in healthy smoking controls, suggesting that the association may not be due to intestinal inflammation but may reflect a direct impact of smoking on the microbiota. These studies were mostly based on the abundance of 16S ribosomal RNA (rRNA) genes. However, it has been shown that quantifying microbial species with 16S rRNA is biased and depending on the region that is being sequenced, conflicting results can be generated, whereas microbiome shotgun sequencing uses all DNA fragments found in a sample to quantify relative abundances of bacteria as well as other organisms. In view of these considerations and the paucity of previous data, this study aimed to compare the gut microbiota composition of smoking with nonsmoking patients with CD, using whole-metagenome sequencing.

**MATERIALS AND METHODS**

**Study Population**

Smoking and nonsmoking patients with CD were identified from 2 prospective cohort studies in France and in the Netherlands. In France, subjects with CD were recruited from 2 Parisian hospitals and the French association for IBD (Association François Aupetit), whereas in the Netherlands, consecutive patients with IBD in an academic hospital scheduled for surveillance colonoscopy were enrolled. For the present investigation, inclusion criteria were age ≥18 years and an established diagnosis of CD according to endoscopic, radiological, and/or histological features. Exclusion criteria were use of antibiotics and bowel cleansing for colonoscopy during the last 2 months before fecal sampling. For each smoking patient with CD, one nonsmoking patient with CD was randomly selected, carefully matched for country, gender, age, and body mass index. Disease activity was taken into account by including only patients with relatively low fecal calprotectin levels or absence of endoscopic inflammation in both groups. Matching for body mass index was only performed for patients in the French cohort.

**Data Collection**

In the framework of both observational studies, patients were asked to collect a stool sample at a regular basis. Concomitantly, disease activity was assessed using the Harvey–Bradshaw index and either fecal calprotectin levels (France) or endoscopic disease activity (the Netherlands). Current smoking status (categorized into yes or no) and daily cigarette consumption were assessed with self-reported questionnaires. The medical records of participants were reviewed for demographic data, disease classification, medications, and comorbidities.

**Sample Preparation and Processing for Sequencing**

Stool samples were collected at home using Sarstedt tubes (Sarstedt, Nümbrecht, Germany) filled with a preservative buffer. On reception, the tubes were stored at −80°C. Sample aliquoting, DNA isolation, and sequencing were outsourced to GATC Biotech (Konstanz, Germany). For the first batch of samples, manual DNA extraction was performed by suspending fecal samples in 250 µL of guanidine thiocyanate 0.1 M Tris (pH 7.5) and 40 µL of 10% N-lauroyl sarcosine. The suspension was then submitted to vigorous bead-beating to release DNA from microbial cells, and DNA extraction was conducted using a standard protocol.

**TABLE 1. Clinical Characteristics of Nonsmoking and Smoking Crohn’s Disease Patients**

| Population source, n (%)       | Nonsmokers (n = 21) | Smokers (n = 21) | P   |
|-------------------------------|---------------------|-----------------|-----|
| France                        | 17 (81)             | 17 (81)         | 1   |
| The Netherlands               | 4 (19)              | 4 (19)          |     |
| Female gender, n (%)          | 16 (76)             | 16 (76)         | 1   |
| Age, median (IQR), yr         | 31 (27–44)          | 31 (28–38)      | 0.95|
| Disease duration, median (IQR), yr | 6 (4–13)          | 9 (4–13)        | 0.28|
| Distribution of disease, n (%)|                    |                 |     |
| L1, ileal disease             | 4 (19)              | 3 (14)          | 1   |
| L2, colonic disease           | 2 (10)              | 3 (14)          |     |
| L3, ileocolonic disease       | 15 (71)             | 15 (71)         |     |
| +L4 upper gastrointestinal    | 2 (10)              | 2 (10)          | 1   |
| disease                      |                     |                 |     |
| Perianal disease, n (%)       | 0 (0)               | 7 (33)          | 0.01|
| Medication use, n (%)         |                     |                 |     |
| Steroids                      | 0 (0)               | 2 (10)          | 0.49|
| 5-aminosalicylic acid         | 6 (29)              | 3 (14)          | 0.45|
| Immunosuppressants            | 9 (43)              | 9 (43)          | 1   |
| Biological                    | 9 (43)              | 11 (52)         | 0.76|
| Antibiotics                   | 0 (0)               | 0 (0)           | 1   |
| Intestinal resection, n (%)   | 0 (0)               | 3 (14)          | 0.23|
| Body mass index, median (IQR), kg/m² | 21 (20–22)      | 22 (20–24)      | 0.42|
| Harvey-Bradshaw index, median (IQR) | 1 (0–2)           | 1 (0–2)         | 0.58|
| Fecal calprotectin level, median (IQR), µg/g | 50 (50–50) | 50 (50–50) | 0.44|
| Daily number of cigarettes, median (IQR) | —                  | 6 (4–10)        | —   |

IQR, interquartile range.
For the second batch of samples, a commercial extraction kit, the QIAamp Stool DNA mini kit (Qiagen, Hilden, Germany) was used. DNA concentrations were measured using Qubit fluorometric quantitation (Life Technologies, Carlsbad, California). DNA libraries were prepared following the manufacturer’s instruction (Illumina, San Diego, California). Fecal DNA was sequenced on a HiSeq 2500 Illumina sequencer. The target of 40 million minimum paired-end reads was generated for each sample and sequencing read length was 100 to 125 bp.

Bioinformatics Processing

FASTQ files were processed using a customized version of MOCAT software. Reads were trimmed and filtered with a quality cutoff of 20. Sequence reads shorter than 45 bp, mapping to Illumina adapters, or to the human genome (version hg19) were discarded. Reads were then mapped against Enterome’s proprietary CD catalog of 4 million genes. The catalog is an enrichment of a previous 3.3 million genes catalog with 700,000 additional complete genes identified from patients with CD. Genes were quantified within a sample using relative abundance measurements, which means that for each gene, the sum of uniquely mapped reads was divided by gene length and by the sum of all genes. Normalized gene abundances were then summarized at different taxonomic and analytical levels: phylum, genus, species, and MetaGenomics Species.

Gene Richness and Taxonomic Diversity

The gene richness for each sample was computed from the raw abundance table after downsizing based on 11 million simulated depth sequencing and 30 repeats. The Shannon index was computed to assess taxonomic diversity at both the genus and species level.

Phylogenetic Annotation

Genes were annotated using BLASTN alignment method against KEGG and RefSeq genomic databases. The gene annotation method was adapted from Li et al. Only the hits with a minimum of 80% of query sequence length and 65% identity were considered in the annotation process. The similarity thresholds for the phylum, genus, and species taxonomic ranges were 65%, 80%, and 95%, respectively. Genes with multiple hits deprived of any consensus (a consensus was defined as 10% of hits having the same annotation) for their taxonomic associations were annotated at a higher taxonomic range until a consensus was established.

FIGURE 1. Phyla composition. A and B, Pie charts of the relative abundances of the major phyla in nonsmoking and smoking patients with CD, respectively. C and D, Bar charts of the phyla composition in nonsmoking and smoking patients with CD, respectively.
Fecal Calprotectin Analysis

In addition to stool sample collection for metagenomic analysis, fecal samples were collected at home using Sarstedt tubes without preservation buffer in the French study. In these samples, fecal calprotectin was measured using an enzyme-linked immunosorbent assay (Bühlmann fCAL ELISA tests; Bühlmann, Schönenbuch, Switzerland) by Merieux Nutrition (Nantes, France). Range values were between 50 µg/g and 3000 µg/g.

Statistical Analysis

Clinical variables were summarized as medians with interquartile ranges (IQRs) or as frequencies with percentages. The Fisher’s exact test was used to compare categorical variables between smokers and nonsmokers. The Wilcoxon’s signed-rank test for paired samples was performed to compare continuous variables between the 2 groups, including metagenomic data after filtering the variables by presence. When comparing the relative abundances of phyla, genera, and species between smokers and nonsmokers, P-values were adjusted using the Benjamini–Hochberg procedure. A P-value lower than 0.05 was considered statistically significant. All statistical analyses were performed using R (version 3.2.1).

Ethical Considerations

The original cohort studies were both approved by the institutional medical ethics committees.

RESULTS

In total, 21 smoking and 21 matched nonsmoking patients with CD (76% of females) with a median age of 31 years were included (Table 1). Ileocolonic disease was the commonest disease localization in both groups (71%). Seven smoking patients had perianal disease, whereas this phenotype was not present in the nonsmoking group (P < 0.01). No other statistically significant differences in clinical characteristics between smoking and nonsmoking patients with CD were observed. The median fecal calprotectin level was 50 µg/g (IQR 50–50 µg/g) in both groups. Those patients without fecal calprotectin levels (4 smoking and 4 nonsmoking subjects) were all in endoscopic remission. The median number of daily cigarette consumption was 6 (IQR 4–10 cigarettes).

The composition of the gut microbiota of all patients was mainly characterized by the phyla Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria (Fig. 1 A–B). There were marked interindividual differences in the 2 dominant phyla Firmicutes and Bacteroidetes, but no significant differences between smokers and nonsmokers were seen at the phylum level (Fig. 1 C–D).

Gene richness was significantly decreased in smokers compared with nonsmokers with median gene counts of 329,600 and 414,100 (P = 0.01), respectively (Fig. 2A). The taxonomic diversity was also lower in smoking patients than in nonsmoking patients, both at the genus level (median Shannon
index 2.06 versus 2.35, \( P < 0.01 \) and the species level (median Shannon index 3.41 versus 3.71, \( P = 0.01 \)) (Fig. 2B–C).

Testing for 94 genera abundant in more than 70% of the studied population, decreased proportions of the genera Collinsella (\( P = 0.02 \)), Enterorhabdus (\( P = 0.02 \)), and Gordonibacter (\( P = 0.02 \)) were observed in smokers compared with nonsmokers (Fig. 3A–C). No statistically significant differences in the relative abundance of species and MetaGenomics Species were detected after correction for multiple testing. However, proportions of several bacterial species previously associated with CD appeared consistently reduced in smokers compared with nonsmokers, including decreased relative abundances of Akkermansia muciniphila (\( P = 0.15 \)) and Butyricoccus pullicaecorum (\( P = 0.26 \)) (Fig. 4A–B). The proportion of Faecalibacterium prausnitzii was also lower in smoking patients with CD (median abundance 1.22%, IQR 0.42%–2.04%) than in nonsmoking patients with CD (median abundance 3.19%, IQR 2.19%–4.98%) (\( P = 0.10 \)) (Fig. 4C).

**DISCUSSION**

Smoking has well-established detrimental effects on CD, but the biological mechanisms for this association are not clear. This study showed that gut microbial gene richness, genus diversity and species diversity were reduced in smokers with CD as compared with nonsmokers with CD. The microbial profile also differed between these groups regarding the relative abundance of bacterial taxa, including decreased proportions of the genera Collinsella, Enterorhabdus, and Gordonibacter among smoking patients. These findings indicate that an altered gut microbiota may underlie the association between smoking and CD.

Phylogenetic diversity and gene richness of the intestinal microbiome are consistently linked to human health and disease. An overall decrease in these ecological measures has been associated with a variety of disorders, including IBD and CD in particular. The observed reduction in gut microbial diversity among smokers in our study is in line with the general perception that this feature is related to an unhealthy state. Accordingly, a greater perturbed microbiota in smoking patients with CD could possibly more readily predispose to the development of disease activity in comparison with nonsmoking patients with CD.

The genera Collinsella, Enterorhabdus, and Gordonibacter belong to the Actinobacteria phylum, which consists of Gram-positive bacteria characterized by high guanine and cytosine contents and has previously been shown less prevalent in healthy smoking individuals. Collinsella spp. have been isolated from patients with CD and a member of this genus previously appeared less prevalent in relatives of patients with CD compared with unrelated controls. Enterorhabdus spp. have been identified

![FIGURE 3](https://academic.oup.com/ibdjournal/article-fig/22/9/2070/4561938/3)  
**FIGURE 3.** Relative abundances of genera in nonsmoking and smoking patients with CD (after log transformation). A, Genus Collinsella. B, Genus Enterorhabdus. C, Genus Gordonibacter.
from mouse models of ileitis and colitis and from the human gut.\textsuperscript{39-42} This genus was found to be associated with a genetic variant of the human leukocyte antigen complex that has been related to inflammatory diseases.\textsuperscript{41} \textit{Gordonibacter} spp. have previously been isolated from the human intestinal tract, including from a patient with CD.\textsuperscript{43-45} These bacteria can produce urolithins,\textsuperscript{44,46} which are metabolites considered to have anti-inflammatory properties.\textsuperscript{47,48} Otherwise, relatively little is known about these bacterial taxa and their potential relationship with smoking or CD, highlighting the need for future studies to explore how these microbes might interact with smoking and CD.

Although not reaching statistical significance after correction for multiple testing, a difference was also observed in the relative abundance of microbes previously implicated in CD. This included a consistent decrease in proportions of \textit{A. muciniphila},\textsuperscript{49,50} \textit{B. pullicaecorum},\textsuperscript{51} and \textit{F. prausnitzii} among smoking patients.\textsuperscript{52,53} As studies have shown that these bacteria can exert anti-inflammatory effects, this could further support the hypothesis of microbes mediating the adverse effects of smoking in CD.

Previous studies examining the impact of smoking on the gut microbiota are limited, especially in patients with CD. An elegant, interventional study, in which healthy smoking individuals underwent controlled smoking cessation, showed significant alterations in the fecal microbiota, including an increase in \textit{Actinobacteria} (high guanine and cytosine content bacteria and \textit{Bifidobacteria}) and a decrease in \textit{Bacteroidetes} (\textit{Prevotella} spp. and \textit{Bacteroides} spp.).\textsuperscript{16,17} A higher number of \textit{Prevotella} spp. and \textit{Bacteroides} spp. (combined) was also found to be associated with smoking in a study reporting on the effects of smoking in patients with active CD.\textsuperscript{18} Using a whole-metagenome shotgun sequencing, we were able to assess the relative abundance of these bacterial taxa separately, finding a reduced proportion of the \textit{Bacteroides} genus (unadjusted \(P = 0.01\)), but not the \textit{Prevotella} genus (unadjusted \(P = 0.59\)). A few studies also documented associations for \textit{F. prausnitzii} and the genus \textit{Anaerostipes} with smoking in CD.\textsuperscript{18,54,55} Collectively, our data partly confirm and expand on previous studies. Although it remains to be established how smoking might affect the composition of intestinal microbes, these results emphasize that differences in the gut microbiome may be involved in the deleterious effects of smoking in CD.

A significant advantage of this study over previous studies was the metagenomic approach, which allowed us to evaluate the whole gut microbial community rather than targeting (specific) 16S rRNA sequences. Moreover, this technique offered a full quantitative assessment of the gut microbiome. To minimize the influence of disease activity, we only included patients who were either in endoscopic remission or had low fecal calprotectin levels.

This study was limited by the relatively small sample size, which might have resulted in a lack of statistical power to identify
more minor but potentially biologically relevant microbial differences. However, the use of a matched design does result in a more powerful study and reduces the risk of identifying confounding variables, although data on diet or other lifestyle factors possibly associated with smoking were not at our disposal. Furthermore, the smoking status of patients was not extensively evaluated. Self-administered questionnaires may carry a risk of miscategorization, but previous studies showed that self-reported data on smoking behavior were fairly accurate.65,57

To conclude, we demonstrated that gut microbial gene richness, genus diversity, and species diversity were decreased in smokers with CD as compared with nonsmokers with CD. This was accompanied by differences in the relative abundance of bacterial taxa, including reduced proportions of the genera Coli-

linsella, Enterorhabdus, and Gordonibacter. In future, larger studies need to evaluate whether intestinal microorganisms mediate the adverse effects of smoking in CD.

REFERENCES

1. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139:1147–1155.
2. Büsch K, da Silva SA, Holton M, et al. Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2014;8:1362–1377.
3. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489–1499.
4. Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insight into the etiology of its effect. J Crohns Colitis. 2014;8:717–725.
5. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462–1471.
6. Lindberg E, Jämerot G, Huitfeldt B. Smoking in Crohn’s disease: effect on localisation and clinical course. Gut. 1992;33:779–782.
7. Parkes J, Carbonnel F, Beaurgeure L, et al. Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology. 1996;110:424–431.
8. Nunes T, Etchevers MJ, García-Sánchez V, et al. Impact of smoking cessation on the clinical course of Crohn’s disease under current therapeutic algorithms: a multicenter prospective study. Am J Gastroenterol. 2016;111:411–419.
9. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65.
10. Manichanh C, Bornel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599–608.
11. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–546.
12. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108(suppl 1):4554–4561.
13. De Filippo C, Cavaleri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107:14691–14696.
14. Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585–588.
15. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–563.
16. Biedermann L, Zeitz J, Mwinjy J, et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One. 2013;8:e59260.
17. Biedermann L, Brühlauer K, Zeitz J, et al. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. Inflamm Bowel Dis. 2014;20:1496–1501.
42. Yang J, Summanen PH, Henning SM, et al. Xylooligosaccharide supplementation alters gut bacteria in both healthy and prediabetic adults: a pilot study. *Front Physiol.* 2015;6:216.

43. Würdemann D, Tindall BJ, Pukall R, et al. *Gordonibacter pamelaeae* gen. nov., sp. nov., a new member of the Coriobacteriaceae isolated from a patient with Crohn’s disease, and reclassification of *Eggerthella hongkongensis* Lau, et al. 2006 as *Paraeggerthella hongkongensis* gen. nov., comb. nov. *Int J Syst Evol Microbiol.* 2009;59:1405–1415.

44. Selma MV, Tomás-Barberán FA, Beltrán D, et al. *Gordonibacter urolithinfaciens* sp. nov., a urolithin-producing bacterium isolated from the human gut. *Int J Syst Evol Microbiol.* 2014;64:2346–2352.

45. Jin JS, Lee KC, Park IS, et al. *Gordonibacter faecihominis* sp. nov., isolated from human faeces. *Antonie Van Leeuwenhoek.* 2014;106:439–447.

46. Selma MV, Beltrán D, García-Villalba R, et al. Description of urolithin production capacity from ellagic acid of two human intestinal *Gordonibacter* species. *Food Funct.* 2014;5:1779–1784.

47. González-Sarrías A, Larrosa M, Tomás-Barberán FA, et al. NF-kappaB-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts. *Br J Nutr.* 2010;104:503–512.

48. Larrosa M, González-Sarrías A, Yáñez-Gascón MJ, et al. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. *J Nutr Biochem.* 2010;21:717–725.

49. Png CW, Lindén SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. *Am J Gastroenterol.* 2010;105:2420–2428.

50. Derrien M, Van Baarlen P, Hoornveld G, et al. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader *Akkermansia muciniphila*. *Front Microbiol.* 2011;2:166.

51. Eeckhaut V, Machiels K, Perrier C, et al. Butyricicoccus pullicaecorum in inflammatory bowel disease. *Gut.* 2013;62:1745–1752.

52. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A.* 2008;105:16731–16736.

53. Sokol H, Seksik P, Furet JP, et al. Low counts of *Faecalibacterium prausnitzii* in colitis microbiota. *Inflamm Bowel Dis.* 2009;15:1183–1189.

54. Li E, Hamm CM, Gulati AS, et al. Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. *PLoS One.* 2012;7:e26284.

55. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol.* 2012;13:R79.

56. Connor Gorber S, Schofield-Hurwitz S, Hardt J, et al. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. *Nicotine Tob Res.* 2009;11:12–24.

57. Yeager DS, Kronick JA. The validity of self-reported nicotine product use in the 2001-2008 National Health and Nutrition Examination Survey. *Med Care.* 2010;48:1128–1132.